While most targeted cancer therapeutics are designed to specifically bind a molecular target for as long of a duration as possible (i.e., kinase inhibitors and receptor blockers), ZMCs do not bind their molecular target (mutant p53) at all. This evidence concerns the gene TP53 and cancer.